
Edit the Disease - or Replace the Liver? examines whether mRNA therapy, gene replacement, CRISPR and base editing could eventually prevent the need for liver transplantation.
Human studies already show that therapeutic mRNA can temporarily replace missing hepatic enzymes, while gene editors can modify hepatocytes after intravenous delivery. Early BEAM-302 results in alpha-1 antitrypsin deficiency are particularly relevant: correcting the PiZ mutation may address both toxic protein accumulation in the liver and inadequate functional protein in the circulation.
The central distinction is that correcting a molecular defect is not the same as restoring a damaged organ. Genetic medicine is most likely to replace transplantation in monogenic diseases treated before fibrosis, portal hypertension or multiorgan injury. It cannot currently reconstruct advanced cirrhotic architecture, rapidly replace lost hepatocyte mass in acute liver failure or reliably eliminate established liver cancer.
Moderna’s personalized melanoma mRNA therapy offers a useful model for sequence-guided cancer treatment, but it is not a proven cure and has not been shown to replace transplantation for HCC. Meanwhile, machine perfusion could eventually allow donor livers to be genetically modified before implantation - transforming transplantation from organ preservation toward active organ repair.
Bottom line: Genetic medicine may eliminate selected indications for liver transplantation before it eliminates transplantation itself. The decisive variable will be timing: correcting the disease before the liver becomes irreversibly damaged.
Flere episoder fra "Trenches in Transplant Surgery"



Gå ikke glip af nogen episoder af “Trenches in Transplant Surgery” - abonnér på podcasten med gratisapp GetPodcast.








